NANS is a joint conference of Congress of Neurological Surgeons and the North American Neuromodulation Society. During the conference, one of the initial takeaways from study results in the neuromodulation space is that neuromodulation devices from companies such as Medtronic, Abbott and SPR Therapeutic are showing promise treating pain.

Medtronic, the MedTech giant reported statistically significant and superior back pain relief using a novel spinal cord stimulation (SCS) waveform, differential target multiplexed (DTM), used to treat patients with chronic pain.

“DTM therapy is the first tailored SCS approach intentionally developed from a novel scientific concept and demonstrated in an RCT,” said Matt Thomas, VP and GM of Medtronic’s stim and early interventions business. “The study demonstrates that DTM therapy provides superior efficacy for patients with chronic back pain compared to conventional stimulation”.

Abbot reported positive results form a multi-center study of 24 patients who used its Proclaim XR Neurostimulation system for chronic pain.

Proclaim XR is a low-dose, recharge-free spinal cord stimulation implant with up to 10-year battery life. Its BurstDR stimulation waveform was designed to mimic natural patterns found in the brain and to use low doses of mild electrical pulses to change pain signals as they travel from the spinal cord to the brain.

SPR Therapeutics claimed that its Sprint Peripheral Nerve Stimulation (PNS) system demonstrated a 63% reduction in average pain intensity at one year following treatment.

The Sprint PNS system is the only PNS system that doesn’t require permanent implantation, according to the company. The study followed in nine patients who used it for 60 days and was published in Pain Practice.

To read more - NANS 2020: Neuromodulation news you need to know